ARGX vs SLN
argenx SE vs Silence Therapeutics plc — AI-powered side-by-side comparison
VS
SLN
Silence Therapeutics plc
48
Watch
| Metric | ARGX | SLN |
|---|
| AI Score |
69
|
48
|
| Price |
$864.40
|
$14.69
|
| P/E Ratio |
31.34×
|
-6.72×
|
| ROE |
17.6%
|
-142.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
68.6%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
74.4
|
| Beta |
-0.022
|
1.351
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus SLN.
ARGX leads by 21 points.
ARGX scores 69/100 (Buy) versus SLN at 48/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
SLN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -99.3% YoY -- this is not a growth story right now — Growth